Company Profile
Allogene Therapeutics Stock Price, News & Catalysts
- Ticker:
- ALLO
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
2.08 USD (+1.46%)
Close
Last updated: August 17, 2026
708M USD
Market cap
Why the stock is moving
As of Aug 17, 2026, ALLO closed up 1.46% at $2.08. No new same-company headline was identified in the current news window.
Company overview
Allogeneic CAR T Company
Allogene Therapeutics develops off-the-shelf CAR T-cell therapies for cancer and autoimmune disease. Its platform is intended to provide readily available treatment without patient-specific cell collection and manufacturing.
Cema-Cel
Cemacabtagene ansegedleucel, or cema-cel, is a CD19-directed AlloCAR T candidate designed for outpatient administration. It has received FDA Regenerative Medicine Advanced Therapy and Fast Track designations in first-line large B-cell lymphoma consolidation.
MRD-Guided Lymphoma Treatment
The pivotal Phase 2 ALPHA3 study evaluates cema-cel in first-line large B-cell lymphoma patients who remain minimal residual disease-positive after standard treatment. This approach seeks to intervene before overt clinical relapse.
ALLO-329
ALLO-329 is a dual-targeting CD19/CD70 AlloCAR T candidate for autoimmune diseases. Its Dagger technology is designed to reduce host rejection and potentially limit dependence on conventional chemotherapy-based lymphodepletion.
Future catalysts
- Clinical and translational data from the Phase 1 RESOLUTION study of ALLO-329 in the fourth quarter of 2026.
- Interim event-free-survival update from the pivotal Phase 2 ALPHA3 study in mid-2027.
- Completion of ALPHA3 enrollment by the end of 2027.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Allogene Therapeutics (ALLO)?
Allogene Therapeutics (ALLO) most recently closed at 2.08 USD, a +1.46% move versus the previous session.
What is the market cap of Allogene Therapeutics (ALLO)?
Allogene Therapeutics currently has a market capitalization of 708M USD on BioPharmSignal.
What does Allogene Therapeutics do?
Allogeneic CAR T Company Allogene Therapeutics develops off-the-shelf CAR T-cell therapies for cancer and autoimmune disease. Its platform is intended to provide readily available treatment without patient-specific cell collection and manufacturing. Cema-Cel Cemacabtagene ansegedleucel, or cema-cel, is a CD19-directed AlloCAR T candidate designed for...
On which exchange is ALLO stock listed?
Allogene Therapeutics (ALLO) is associated with NASDAQ, United States, Biopharma.
What is ALLO-329?
Clinical and translational data from the Phase 1 RESOLUTION study of ALLO-329 in the fourth quarter of 2026.
Which conditions is Allogene Therapeutics targeting with ALLO-329?
Allogene Therapeutics is associated with cancer therapeutics based on its company overview and current catalyst commentary.
How does Allogene Therapeutics describe recent progress with ALLO-329?
Clinical and translational data from the Phase 1 RESOLUTION study of ALLO-329 in the fourth quarter of 2026.
What is Allogeneic?
Allogeneic CAR T Company Allogene Therapeutics develops off-the-shelf CAR T-cell therapies for cancer and autoimmune disease.